[Retracted] Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status

Table 2

Osimertinib and supplementary treatments for LM.

Characteristics	Osimertinib with T790M, n = 28 (%)	Osimertinib without T790M, n = 16 (%)	First-/second-generation EGFR-TKI, n = 34 (%)
Treatments prior to LM
Gefitinib only	5 (17.9)	8 (50.0)	11 (32.4)
Erlotinib only	2 (7.1)	2 (12.5)	7 (20.6)
Icotinib only	6 (21.4)	1 (6.3)	0 (0)
Afatinib and gefitinib	3 (10.7)	2 (12.5)	0 (0)
Osimertinib	5 (17.9)	1 (6.3)	0 (0)
Cytotoxic chemotherapy	15 (53.6)	11 (68.8)	9 (26.5)
WBRT	3 (10.7)	3 (1 8.8)	5 (14.7)
Median duration of osimertinib treatment, months (95% CI)	7.0 (4.0–10.0)	7.0 (1.5–10.0)	—
Osimertinib treatment line
1^st line	0	4 (25.0)	—
2^nd line	17 (60.7)	8 (50.0)	—
3^rd line	11 (39.3)	4 (25.0)	—
Osimertinib dosage
80 mg/day	19 (67.9)	12 (75.0)	—
160 mg/day	9 (32.1)	4 (25.0)	—
Supplementary treatments
Cytotoxic chemotherapy	17 (60.7)	11 (68.8)	12 (38.7)
WBRT	5 (17.9)	3 (18.8)	4 (12.9)
IT chemotherapy	7 (25.0)	5 (31.3)	2 (6.5)
VPS	3 (10.7)	4 (25.0)	3 (9.7)

Note. LM: Leptomeningeal metastasis, WBRT: whole-brain radiation, IT: intrathecal, and VPS: ventriculoperitoneal shunt.